Home » Stocks » ACOR

Acorda Therapeutics, Inc. (ACOR)

Stock Price: $4.24 USD -0.36 (-7.83%)
Updated May 10, 2021 2:23 PM EDT - Market open
Market Cap 43.65M
Revenue (ttm) 152.97M
Net Income (ttm) -99.59M
Shares Out 8.08M
EPS (ttm) -12.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $4.24
Previous Close $4.60
Change ($) -0.36
Change (%) -7.83%
Day's Open 4.50
Day's Range 4.24 - 4.55
Day's Volume 188,851
52-Week Range 2.53 - 9.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2021 Financial Results

3 days ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

1 week ago - Business Wire

Acorda (ACOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago - Zacks Investment Research

ARDSLEY, N.Y.--(BUSINESS WIRE)--Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela”.

4 weeks ago - Business Wire

Is (ACOR) Outperforming Other Medical Stocks This Year?

2 months ago - Zacks Investment Research

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

2 months ago - Business Wire

Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

2 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

2 months ago - Business Wire

Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Departure of Chief, Business Operations

2 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

2 months ago - Business Wire

During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.

3 months ago - Zacks Investment Research

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.

3 months ago - Zacks Investment Research

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachu...

3 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care Co...

3 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11th -14th H.C. Wainwright...

3 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shar...

4 months ago - Business Wire

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Acorda (ACOR) delivered earnings and revenue surprises of 23.33% and 80.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of Acorda Therapeutics (NASDAQ:ACOR) increased 8.33% after the company reported Q3 results. Quarterly Results Earnings per share rose 50.00% over the past year to ($0.23), which beat the estimate...

6 months ago - Benzinga

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the third quarter ended September 30, 2020. “We are encouraged by the 24% increase in INB...

6 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, Novem...

6 months ago - Business Wire

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 0.66% after the company reported Q2 results.

9 months ago - Benzinga

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.

9 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.

9 months ago - Business Wire

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.

9 months ago - Business Wire

Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.

1 year ago - Zacks Investment Research

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.

1 year ago - Zacks Investment Research

Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.

1 year ago - Zacks Investment Research

Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.

1 year ago - Zacks Investment Research

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.

1 year ago - Zacks Investment Research

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Acorda (ACOR) delivered earnings and revenue surprises of 63.41% and 11.88%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Acorda (ACOR) reports lower-than-expected loss in the fourth quarter while revenues beat estimates.

1 year ago - Zacks Investment Research

During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.

1 year ago - Zacks Investment Research

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22... [Read more...]

Industry
Biotechnology
IPO Date
Feb 10, 2006
CEO
Ron Cohen
Employees
167
Stock Exchange
NASDAQ
Ticker Symbol
ACOR
Full Company Profile

Financial Performance

In 2020, ACOR's revenue was $152.97 million, a decrease of -20.50% compared to the previous year's $192.41 million. Losses were -$99.59 million, -63.51% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ACOR stock is "Buy." The 12-month stock price forecast is 17.50, which is an increase of 312.74% from the latest price.

Price Target
$17.50
(312.74% upside)
Analyst Consensus: Buy